[Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
Keppel Hesselink
J M
JM
D014150:Antipsychotic Agents / Q000378:metabolism; D005473:Fluoxetine / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D012702:Serotonin Antagonists / Q000378:metabolism*
D014150:Antipsychotic Agents; D012702:Serotonin Antagonists; D005473:Fluoxetine
Parkinsonisme na toevoeging van fluoxetine aan behandeling met neuroleptica of carbamazepine.